How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes (MINING)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Immune-related Adverse Events (irAEs) [ Time Frame: 2 years ]
Electronic medical records will be queried for specific drug-related adverse events known as immune-related Adverse Events (irAEs) including but not limited to colitis, hypophysitis, hepatitis, pneumonitis, pancreatitis, arthritis, rash, and vitiligo.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with skin cancer planning to initiate or already on ANY type of immunotherapy.
≥18 years of age.
Diagnosis of skin cancer.
Planning to initiate or already on ANY type of immunotherapy.
Able to provide urine and stool specimens.
Major GI surgery in the past 5 years other than cholecystectomy and appendectomy.